3PC-017 Impact of agitation on pembrolizumab (Keytruda®) safety and efficacy: aggregation and functionality

A Torrente-López; R Pérez-Robles; J Hermosilla; J Ruiz-Travé; MA Hernández-García; A Torres; J Cabeza; A Salmerón-García; N Navas

doi:10.1136/ejhpharm-2023-eahp.40

Article info

PDF

Section 3: Production and compounding

3PC-017 Impact of agitation on pembrolizumab (Keytruda^®) safety and efficacy: aggregation and functionality

Free

Authors

A Torrente-López Biomedical Research Institute Ibs Granada, Analytical Chemistry-Science Faculty-University of Granada, Granada, Spain PubMed articles Google scholar articles
R Pérez-Robles Biomedical Research Institute Ibs Granada, Analytical Chemistry-Science Faculty-University of Granada, Granada, Spain PubMed articles Google scholar articles
J Hermosilla Biomedical Research Institute Ibs Granada, Analytical Chemistry-Science Faculty-University of Granada, Granada, Spain PubMed articles Google scholar articles
J Ruiz-Travé Biomedical Research Institute Ibs Granada, Analytical Chemistry-Science Faculty-University of Granada, Granada, Spain PubMed articles Google scholar articles
MA Hernández-García Biomedical Research Institute Ibs Granada, Analytical Chemistry-Science Faculty-University of Granada, Granada, Spain PubMed articles Google scholar articles
A Torres Biomedical Research Institute Ibs Granada, Analytical Chemistry-Science Faculty-University of Granada, Granada, Spain PubMed articles Google scholar articles
J Cabeza Biomedical Research Institute Ibs Granada, Clinical Pharmacy-San Cecilio University Hospital, Granada, Spain PubMed articles Google scholar articles
A Salmerón-García Biomedical Research Institute Ibs Granada, Clinical Pharmacy-San Cecilio University Hospital, Granada, Spain PubMed articles Google scholar articles
N Navas Biomedical Research Institute Ibs Granada, Analytical Chemistry-Science Faculty-University of Granada, Granada, Spain PubMed articles Google scholar articles

Citation

Torrente-López A, Pérez-Robles R, Hermosilla J, et al

3PC-017 Impact of agitation on pembrolizumab (Keytruda^®) safety and efficacy: aggregation and functionality

European Journal of Hospital Pharmacy 2023;30:A18.

Publication history

First published March 23, 2023.

Online issue publication

May 02, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Main menu

Authors

Citation

Publication history

Request permissions

Copyright information

Log in using your username and password

Main menu

Log in using your username and password

You are here

Authors

Citation

Publication history

Request permissions

Copyright information

Read the full text or download the PDF:

Log in using your username and password